Summary of Study ST001014

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000680. The data can be accessed directly via it's Project DOI: 10.21228/M8S684 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis | Show all samples | Show named metabolites | Download named metabolite data
Download mwTab file (text) | Download mwTab file(JSON)

Study ID	ST001014
Study Title	Sphingolipid Concentrations in Serum for Muscle Wasting in Cancer Cachexia (part-IX)
Study Summary	Sphingolipid Concentrations of Muscle Wasting in Cancer Cachexia. Serum samples from 10 control patients, 10 weight stable pancreatic cancer patients, and 10 pancreatic cancer patients with significant weight loss. Samples are divided evenly between males and females.
Institute	Mayo Clinic
Last Name	Guttridge
First Name	Denis
Address	520 Biomedical Research Tower 460 W. 12th Avenue Columbus, OH 43210
Email	denis.guttridge@osumc.edu
Phone	614-688-3137
Submit Date	2018-07-15
Analysis Type Detail	LC-MS
Release Date	2020-07-15
Release Version	1

Select appropriate tab below to view additional metadata details:

Project:

Project ID:	PR000680
Project DOI:	doi: 10.21228/M8S684
Project Title:	Mayo Pilot and Feasibility: Metabolomics of Muscle Wasting in Cancer Cachexia
Project Summary:	Cachexia is a debilitating syndrome that results in severe, involuntary weight loss due to the depletion of skeletal muscle mass. This syndrome occurs in a majority of cancers and contributes to approximately one third of all cancer deaths. Currently, no effective therapy exists to combat this malignant disorder, and disappointing results from recent Phase III clinical trials indicate that a cachexia treatment is not likely to appear soon. Thus, it is clear that greater knowledge of the mechanisms driving muscle wasting in cachexia is needed in order to identify new therapeutic targets and stimulate new clinical trials. Our approach to gaining this knowledge has been to work with muscle biopsies from pancreatic cancer patients, since this population is highly prone to cachexia. We have also been expanding our studies beyond the classical mouse models of cancer cachexia in hopes of finding a new model that better recapitulates the human disease. We recently undertook RNA-Seq analysis comparing muscle biopsies from pancreatic cancer patients with and without cachexia, which has been exciting since this type of analysis has not yet been performed in patient samples. Preliminary results revealed that cachectic muscle was associated with alterations in metabolism. These data provide the rationale for performing metabolomics to ascertain whether specific metabolic pathways or metabolites can be identified as potential drivers of muscle wasting in cachexia or be used as biomarker of cachexia, which the field desperately needs. An additional need is a well-validated animal model of cancer cachexia that accurately reflects the human condition, which can be used to test mechanisms and pre-clinical compounds. We propose to perform these studies under the Mayo Clinic Metabolomics Resource Core Pilot and Feasibility Grant program to: 1) Identify metabolic alterations and biomarkers of pancreatic cancer-induced muscle wasting; and 2) Identify a suitable mouse model that recapitulates the metabolic imbalance of muscles from pancreatic cancer cachexia patients. By performing these studies, we will accelerate our understanding of the underlying causes of muscle wasting, which should translate to improving the current pipeline of anticachexia therapies.
Institute:	Mayo Clinic
Last Name:	Guttridge
First Name:	Denis
Address:	520 Biomedical Research Tower 460 W. 12th Avenue Columbus, OH 43210
Email:	denis.guttridge@osumc.edu
Phone:	614-688-3137

Subject:

Subject ID:	SU001053
Subject Type:	Human
Subject Species:	Homo sapiens
Taxonomy ID:	9606

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id	local_sample_id	Grouping	Gender
SA063612	ms6652-18	Control	Female
SA063613	ms6652-7	Control	Female
SA063614	ms6652-9	Control	Female
SA063615	ms6652-4	Control	Female
SA063616	ms6652-3	Control	Female
SA063617	ms6652-10	Control	Male
SA063618	ms6652-20	Control	Male
SA063619	ms6652-27	Control	Male
SA063620	ms6652-15	Control	Male
SA063621	ms6652-2	Control	Male
SA063622	ms6652-1	Weight Losing	Female
SA063623	ms6652-22	Weight Losing	Female
SA063624	ms6652-21	Weight Losing	Female
SA063625	ms6652-26	Weight Losing	Female
SA063626	ms6652-29	Weight Losing	Female
SA063627	ms6652-6	Weight Losing	Male
SA063628	ms6652-5	Weight Losing	Male
SA063629	ms6652-14	Weight Losing	Male
SA063630	ms6652-30	Weight Losing	Male
SA063631	ms6652-13	Weight Losing	Male
SA063632	ms6652-25	Weight Stable	Female
SA063633	ms6652-24	Weight Stable	Female
SA063634	ms6652-16	Weight Stable	Female
SA063635	ms6652-17	Weight Stable	Female
SA063636	ms6652-19	Weight Stable	Female
SA063637	ms6652-8	Weight Stable	Male
SA063638	ms6652-11	Weight Stable	Male
SA063639	ms6652-28	Weight Stable	Male
SA063640	ms6652-23	Weight Stable	Male
SA063641	ms6652-12	Weight Stable	Male

Showing results 1 to 30 of 30

Showing results 1 to 30 of 30

Collection:

Collection ID:	CO001047
Collection Summary:	Tissue and blood donated from Cancer Cachexia Program at Ohio State University
Sample Type:	Blood (serum)

Treatment:

Treatment ID:	TR001067
Treatment Summary:	Cancer cachexia is a multi-factorial syndrome accompanying advanced cancer, with the most notable symptom being unintentional weight loss. Cachectic patients lose both adipose tissue and skeletal muscle, with skeletal muscle loss and its associated weakness contributing to the morbidity and mortality of these patients. Despite three decades of research into mechanisms driving muscle wasting due to cancer, to date, an approved pharmacological therapy to prevent or treat cancer cachexia is still lacking. Our laboratory focuses on cancer cachexia in patients with pancreatic cancer, as up to 85% of these patients experience weight loss. Cachexia often occurs early in the progression of pancreatic cancer, making clear that cachexia in these patients is not simply a result of end-stage disease. Further, with perhaps more than ¼ of all pancreatic cancer deaths resulting from muscle weakness as opposed to tumor burden, cachexia also significantly contributes to mortality due to pancreatic cancer. Because little progress has been made in improving treatment outcomes, addressing cancer-induced muscle wasting is perhaps the best strategy to prolong pancreatic cancer patient survival and increase patient quality of life. In an effort to better understand the mechanisms driving pancreatic cancer-induced muscle wasting, the Cancer Cachexia Program at Ohio State University has begun a Pancreatic Cancer Cachexia Tissue Bank. To date, over 130 patients undergoing attempted resection for pancreatic cancer or other abdominal surgeries have donated muscle and blood to our bank. A unique aspect of our tissue bank is our focus on patients eligible for resection. In contrast to other studies using patients with late-stage disease, our patients are not end-stage, as they are considered healthy enough to undergo a major operation.

Treatment ID:

TR001067

Treatment Summary:

Cancer cachexia is a multi-factorial syndrome accompanying advanced cancer, with the most notable symptom being unintentional weight loss. Cachectic patients lose both adipose tissue and skeletal muscle, with skeletal muscle loss and its associated weakness contributing to the morbidity and mortality of these patients. Despite three decades of research into mechanisms driving muscle wasting due to cancer, to date, an approved pharmacological therapy to prevent or treat cancer cachexia is still lacking. Our laboratory focuses on cancer cachexia in patients with pancreatic cancer, as up to 85% of these patients experience weight loss. Cachexia often occurs early in the progression of pancreatic cancer, making clear that cachexia in these patients is not simply a result of end-stage disease. Further, with perhaps more than ¼ of all pancreatic cancer deaths resulting from muscle weakness as opposed to tumor burden, cachexia also significantly contributes to mortality due to pancreatic cancer. Because little progress has been made in improving treatment outcomes, addressing cancer-induced muscle wasting is perhaps the best strategy to prolong pancreatic cancer patient survival and increase patient quality of life. In an effort to better understand the mechanisms driving pancreatic cancer-induced muscle wasting, the Cancer Cachexia Program at Ohio State University has begun a Pancreatic Cancer Cachexia Tissue Bank. To date, over 130 patients undergoing attempted resection for pancreatic cancer or other abdominal surgeries have donated muscle and blood to our bank. A unique aspect of our tissue bank is our focus on patients eligible for resection. In contrast to other studies using patients with late-stage disease, our patients are not end-stage, as they are considered healthy enough to undergo a major operation.

Sample Preparation:

Sampleprep ID:	SP001060
Sampleprep Summary:	sphingolipid concentrations using serum

Combined analysis:

Analysis ID	AN001656
Analysis type	MS
Chromatography type	Reversed phase
Chromatography system	Waters Acquity
Column	Waters Acquity BEH C8 (150 x 2mm,1.7um)
MS Type	ESI
MS instrument type	Triple quadrupole
MS instrument name	Thermo Quantum Ultra
Ion Mode	POSITIVE
Units	uM

Chromatography:

Chromatography ID:	CH001167
Instrument Name:	Waters Acquity
Column Name:	Waters Acquity BEH C8 (150 x 2mm,1.7um)
Chromatography Type:	Reversed phase

MS:

MS ID:	MS001531
Analysis ID:	AN001656
Instrument Name:	Thermo Quantum Ultra
Instrument Type:	Triple quadrupole
MS Type:	ESI
Ion Mode:	POSITIVE